대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	The comparison of febuxostat and allopurinol in chronic gout patients with chronic kidney disease, a randomized prospective study.
저자	Yong Chul Kim*
출판정보	2016; 2016(1):
키워드	chronic kidney disease, Febuxostat, gout
초록	Background: The aim of this 12-week, open-label, non-inferiority trial was to compare the safety and efficacy of febuxostat with allopurinol in treating chronic gout patients with chronic kidney disease (CKD). Methods: Patients were randomized to febuxostat (n= 53; 40mg daily for the first 4 weeks, 80mg thereafter) or allopurinol (n=53; dose adjusted based on ones kidney function), and both groups were stratified by baseline serum uric acid (SUA) 10.0 mg/dL. SUA was checked for 4 times (week2, 4, 8, 12) The primary end point was the proportion of SUA below 6.0 mg/dL at the end of the study. The non-inferiority margin for the difference in rates (of SUA below 6.0 mg/dL) was defined as -15 %. Efficacy analyses were done both by intention-to-treat (ITT) and per protocol (PP). Results: Uric acid control with febuxostat (n= 49, 94.2 %) was non-inferior to that achieved with allopurinol (n= 13, 26 %), difference 0.68 [97.5 % CI 0.54 to ∞]. The proportion of SUA below 6.0 mg/dL at week 2 was 57.69 % (febuxostat) and 12% (allopurinol), respectively. And the rate increased in both group to 94.23 % (febuxostat), 26 % (allopurinol) at week 12 (p<0.0001). The rate of GFR change or incidence of AKI had no difference in both group. Skin eruption was observed in 1 case with allopurinol, but was tolerable. Conclusion: Febuxostat was as effective as allopurinol in reducing SUA in chronic gout patients with CKD, with a similar safety profile. Table: Table 1. Baseline characteristics of the participants
원문(PDF)	PDF 원문보기

목록

위로가기